Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Author's Avatar
Jul 20, 2022

FDA acknowledges that data from a randomized withdrawal period of Study C602 have the potential to support an NDA submission